Profit margin of Exelixis, Inc.
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
|PLPM Planet Payment, Inc.||NASDAQ > Miscellaneous > Business Services||0.48|
|TRST TrustCo Bank Corp NY||NASDAQ > Finance > Major Banks||0.48|
|SCHL Scholastic Corporation||NASDAQ > Consumer Services > Books||0.48|
|HDNG Hardinge Inc.||NASDAQ > Capital Goods > Industrial Machinery/Components||0.49|
|CLF Cliffs Natural Resources Inc.||NYSE > Basic Industries > Precious Metals||0.49|
|KL Kirkland Lake Gold Ltd.||NYSE > Basic Industries > Precious Metals||0.49|
|EXEL Exelixis, Inc.||NASDAQ > Health Care > Biotechnology: Commercial Physical & Biological Resarch||0.49|
|HCC Warrior Met Coal, Inc.||NYSE > Energy > Coal Mining||102.00|
|WTM White Mountains Insurance Group, Ltd.||NYSE > Finance > Property-Casualty Insurers||128.23|
|NVR NVR, Inc.||NYSE > Capital Goods > Homebuilding||135.95|
|SEB Seaboard Corporation||NYSEMKT > Finance > Investment Bankers/Brokers/Service||279.36|
|DCIX Diana Containerships Inc.||NASDAQ > Transportation > Marine Transportation||648.16|
|BRK-A Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||11,356.35|